Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
EV/GP
Enterprise Value to Gross Profit
Market Cap | EV/GP | ||||
---|---|---|---|---|---|
US |
Sonoma Pharmaceuticals Inc
NASDAQ:SNOA
|
2.4m USD | 0 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -164 697 976 | |
US |
Eli Lilly and Co
NYSE:LLY
|
697.9B USD | 26.4 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 1 026 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
3.8T DKK | 19.2 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
357.8B USD | 6.3 | ||
US |
Merck & Co Inc
NYSE:MRK
|
323.8B USD | 7.5 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
186.8B GBP | 53.3 | ||
CH |
Novartis AG
SIX:NOVN
|
179.8B CHF | 5.9 | ||
CH |
Roche Holding AG
SIX:ROG
|
173.2B CHF | 4.4 | ||
US |
Pfizer Inc
NYSE:PFE
|
155.7B USD | 5.2 |
EV/GP Forward Multiples
Forward EV/GP multiple is a version of the EV/GP ratio that uses forecasted gross profit for the EV/GP calculation. 1-Year, 2-Years, and 3-Years forwards use gross profit forecasts for 1, 2, and 3 years ahead, respectively.